Shanghai Fanghe Investment Center is a professional fund management firm specializing in investment management and asset management, founded in 2015. The Company’s core business focuses on equity investments in growth-stage projects within emerging industries, with particular emphasis on the internet, healthcare, and consumption upgrade sectors. It has established a broad investment network in areas such as technology promotion, pharmaceutical manufacturing, and consumer services, consistently identifying the value of high-growth enterprises.

By leveraging the deep industry insights of its professional investment team, the company has constructed a diversified investment portfolio covering multiple sectors, including technology promotion, pharmaceutical manufacturing, software services, and consumer services. As an active capital platform, it provides continuous support to high-growth enterprises through disciplined and rigorous investment strategies, demonstrating strong resource integration capabilities and superior market adaptability in the equity investment field.

Key portfolio companies include: Novogene Co., Ltd. (listed on the Shanghai Stock Exchange in 2021) and Wuhan Abogen Biosciences Co., Ltd. (IPO).